Product Pipeline

Our goal is to be the leading biopharmaceutical company developing and marketing therapies that restore function and improve the lives of people with neurological disorders.

Acorda’s R&D efforts are designed to:

• Determine if dalfampridine is a therapeutic option for people with post-stroke walking deficits
• Develop CVT-301 as a potential treatment for OFF episodes in people with Parkinson’s disease
• Assess the potential of PLUMIAZ^® as a treatment for people with epilepsy who experience cluster seizures
• Advance clinical development of rHIgM22, a remyelinating antibody, as a potential treatment for people with MS
• Further clinical development of cimaglermin (GGF2) for the treatment of people with heart failure; Acorda is also interested in studying cimaglermin as a potential treatment in several neurological applications
• Advance other clinical and preclinical stage products in our pipeline, which have potential therapeutic value in neurological conditions such as MS, spinal cord injury, stroke, and traumatic brain injury